Roth MKM Maintains Buy on Biote, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst George Kelly has maintained a Buy rating on Biote (NASDAQ: BTMD) but has reduced the price target from $8 to $7.

January 18, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Roth MKM analyst George Kelly continues to recommend Biote with a Buy rating, although the price target has been decreased from $8 to $7.
The maintenance of a Buy rating suggests a positive outlook on Biote's fundamentals or growth prospects. However, the reduction in the price target could reflect a revised valuation model, potentially due to new market information or recalibrated expectations. This mixed signal may lead to a neutral short-term impact on the stock price as investors weigh the positive rating against the lower price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100